Dr. Daniel Öberg has a PhD in medical virology with a specialisation in anticancer gene therapy. He completed five years of postdoctoral oncolytic research at the Institute of Cancer, London. He has since been working for four years as an assistant professor at Uppsala University.
Daniel has developed and experimented with the vector Ixovex. He has lectured at M.Sc. level ion various topics including general and specific virology, gene therapy, ”virus and cancer” and ”virus and immune defence”.
Kevin Harrington PhD – Board Member
Professor Kevin Harrington is Joint Head of the Division of Radiotherapy and Imaging at the Institute of Cancer Research. He is a specialist in Head and Neck cancer and in melanoma. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists.
Prof Harrington has translated numerous therapies into clinical trial, particularly in the field of head-and-neck cancer providing Ixogen with invaluable experience.
Alan Melcher PhD – Board Member
Professor Alan Melcher moved to The Institute of Cancer Research, London, as Professor of Translational Immunology and Honorary Consultant Oncologist at The Royal Marsden NHS Foundation Trust. He combines a clinical practice in head and neck cancer and melanoma research focused on oncolytic viruses and immunotherapy for the treatment of cancer.
He Holds a PhD at the Imperial Cancer Research Fund (now Cancer Research UK) and prior he was a post-doctoral research fellow at the Mayo Clinic, Minnesota. He became Professor of Clinical Oncology and Biotherapy in Leeds in 2007.
Professor Alan Melcher graduated in medicine from the University of Oxford in 1989, and trained in Clinical Oncology (Radiotherapy and Chemotherapy) in Cardiff, London and Leeds.
Dr Martin Forster PhD – Board Member
Martin completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. He has been running a research-based practice and has been principal / chief investigator for more than 20 early and late phase clinical trials while working in cancer care and training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts.
Martin is involved in the management of patients with both lung and head and neck cancers and has a particular interest in the cancer biology that leads to the development of both lung and head and neck cancers.
Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. He holds a PhD at the Institute for Cancer Research, London and was awarded the EORTC-PAMM Young Investigator Award in 2004.
Professor Ghassan Alusi PhD FRCS (ORL-HNS) - Chairman and Chief Executive Officer
Ghassan is the founding partner and CEO of PsiVac Ltd.
Ghassan is a consultant ENT, Head and Neck surgeon specialising in Head and Neck malignancy at Barts Health as well as an honorary consultant surgeon at University College Hospital. He has setup the Head and Neck Academic Centre with Prof. Mark McGurk, where he holds an academic position of Honorary Professor. He is also Honorary Professor at at the William Harvey Institute, Queen Mary’s where he co-supervises 2 PhD fellows currently. Prior to this, he co-supervised 12 PhDs, including 9 in the field of oncolytic viruses. This work has produced many peer reviewed publications.
Ghassan holds a PhD degree from University of Leicester and FRCS (ORL-NHS)
